On 30 Oct 2026, Clinitech Laboratory was priced at ₹30.00, or 16.4× trailing earnings, and the shares are 36% below their 52-week high. It earns ROCE of 6.3% and ROE of 4.6%, and sales grew 14% a year over 3 years while net profit fell 12%. The company has almost no debt. It is a small-cap company with a market cap of ₹6.85 Cr; the shares fell 29% over the past year.
- ₹30.00
- ₹30.00
- ₹30.00
- ₹30.00
- 1.2K
Health check
- ReturnsWeak
−28.6% over the past year.
- Price tagNo peers
P/E 16.4, with no peers to compare.
- GrowthSlow
Sales +14.3%, profit −12.0% a year over 3 years.
- ProfitabilityWeak
ROCE 6.3%.
- Balance sheetSolid
Debt 0.06× equity, interest covered 31.5×.
- Red flags3 to check
Return on equity is low at 4.6%.
Small cap
Defensive
Key metrics
- Market cap
- ₹6.85 Cr
- Small cap
- P/E
- 16.4
- Price to book
- 0.74
- Book value ₹40.52
- Dividend yield
- 0.00%
- ROE
- 4.6%
- Return on equity
- ROCE
- 6.3%
- Return on capital employed
- Debt to equity
- 0.06
- Debt ₹0.54 Cr
- EPS (TTM)
- ₹1.83
- OPM (TTM)
- 5.0%
- Net margin 4.4%
- Sales growth
- +6.1%
- Latest quarter vs a year ago
- Profit growth
- −26.8%
- Latest quarter vs a year ago
- Price to sales
- 0.72
- EV/EBITDA 5.2
Strengths and risks
Strengths
- Practically debt-free.
Risks to check
- Return on equity is low at 4.6%.
- Quarterly profit down 26.8% on a year ago.
- 36% below its 52-week high.
About Clinitech Laboratory
Clinitech Laboratory Limited provides healthcare services in India. The company provides services including pathology testing laboratories, diagnostic centers, scan centers, X-ray and ECG clinics, and other services. The company was founded in 1990 and is headquartered in Navi Mumbai, India.
- Headquarters
- Navi Mumbai
- Employees
- 162
- Sector
- Healthcare
- ISIN
- INE0QMR01015
- Website
- ctllab.in
Price range
- Avg volume (3M)
- 174
- 1-year return
- minus 28.6%
- From 52-week high
- minus 36.4%
Peers
We couldn’t find listed peers for this company.
Quarterly results
This company doesn’t report these figures in a format we can read yet.
Profit & loss
- Sales CAGR 3Y
- +14.3%
- Profit CAGR 3Y
- −12.0%
- ROE
- 4.6%
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 6.3 | 6.4 | 8.2 | 9.5 | |
| – | +0.9% | +28.6% | +15.3% | |
| 5 | 5.4 | 7.4 | 8.5 | |
| 1.4 | 1 | 0.8 | 1 | |
| 21.9% | 15.8% | 10.1% | 10.8% | |
| 0 | −0 | 0.1 | 0.1 | |
| 0.1 | 0.1 | 0 | 0 | |
| 0.4 | 0.4 | 0.4 | 0.5 | |
| −0 | 0 | 0.1 | – | |
| 0.9 | 0.5 | 0.6 | 0.6 | |
| 29.0% | 26.5% | 28.8% | 30.4% | |
| 0.6 | 0.4 | 0.4 | 0.4 | |
| – | minus 39.5% | +6.3% | +5.9% | |
| 2.69 | 1.63 | 1.90 | – |
Forecast
Balance sheet
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 1.5 | 1.7 | 2.3 | 2.3 | |
| 0.9 | 1.9 | 6.5 | 7 | |
| 1 | 0.9 | – | 0.5 | |
| 2.6 | 1.2 | 2 | 1.4 | |
| 6 | 5.6 | 10.8 | 11.2 | |
| 3.8 | 1.7 | 3.1 | 2.4 | |
| 2.5 | 0.9 | – | 0.3 | |
| – | – | – | 0.1 | |
| 0.8 | 0.7 | 3.1 | 2.1 | |
| −1 | 2.3 | 4.6 | 6.3 | |
| 6 | 5.6 | 10.8 | 11.2 |
Cash flow
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 1.2 | −1.3 | −0.9 | −0.8 | |
| −0.7 | 0.8 | −0.7 | −0.7 | |
| 0.1 | 0.4 | 4 | 0.5 | |
| 0.7 | −0.1 | 2.4 | −1 | |
| −0.3 | −1.2 | −1.2 | −0.8 | |
| 1 | −2.5 | −2 | −1.6 |
Shareholding pattern
This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.
Major shareholders
Filings & events
News
No recent news coverage found.